Harshini Ramaswamy

Articles by Harshini Ramaswamy

26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

ByWilliam Audeh, MD,Harshini Ramaswamy,Andrea Menicucci

July 27th 2024

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

ByWilliam Audeh, MD,Nicole Chmielewski-Stivers,Harshini Ramaswamy,Andrea Menicucci

June 30th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test

Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy

Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Patient-Centered Treatment Transitions in HR+/HER2− mBC